Trichomonas Vaginalis Antimicrobial Resistance Activity— SSuN, 2008–2010 Robert D. Kirkcaldy, MD, MPH Epidemic Intelligence Service (EIS) Officer Division.

Slides:

Advertisements

Similar presentations

Analytical Sensitivity of the Urine-Based APTIMA® Trichomonas vaginalis molecular assay using the automated Tigris® Platform A.H. Freeman1, M.W. Pandori2,

Advertisements

Sexually Transmitted Disease Surveillance 2012 Division of STD Prevention.

CDC Initiative in Worksite Health Promotion Jason E. Lang, MPH, MS Team Lead, Workplace Health Programs National Center for Chronic Disease Prevention.

Sexually Transmitted Disease Surveillance 2012 Division of STD Prevention 2012 Data.

Sexually Transmitted Diseases Among Men Who Have Sex with Men: A need for new prevention and research strategies National Sexually Transmitted Disease.

Repeat Chlamydia trachomatis: Rate and Predictors among Males Eileen F. Dunne M.D., M.P.H. JB Chapin, C Rietmeijer, CK Kent, J Ellen, C Gaydos, N Willard,

Risk Factors for Early Syphilis Among Men Who Have Sex With Men Seen in an STD Clinic – San Francisco, STD Prevention Conference: March 10, 2004.

Sexually Transmitted Disease Surveillance 2013 Division of STD Prevention.

PMTCT FAILURE: THE ROLE OF MATERNAL AND FACILITY –RELATED FACTORS ICASA Presentation 8 th to 12 th Dec 2013 Onono Maricianah 1, Elizabeth A. Bukusi 1,

Lisa Grohskopf, MD, MPH Medical Officer Influenza Division Centers for Disease Control and Prevention U.S. Influenza Surveillance National Center for Immunization.

Role of Health Information Technology in Nationwide Outbreaks Chesley Richards, MD, MPH Director, Office of Public Health Scientific Services Centers for.

STDs in Adolescents and Young Adults Sexually Transmitted Disease Surveillance 2009 Division of STD Prevention.

Steven J Shapiro Infertility Prevention Project Coordinator Program and Training Branch Infertility Prevention Project Region I Wells, Maine June 6-7,

Gonococcal Isolate Surveillance Project (GISP)

HIV Partner Notification in the U.S.: A National Survey of Program Coverage and Outcomes Matthew Golden MD, MPH Assistant Professor of Medicine, UW Medical.

Linked Testing Using Rapid HIV Tests for Antenatal Care Sentinel Surveillance in Resource-Limited Settings Evidence from Angola’s Experience in 2009 James.

Risk factors for Incident Trichomonas vaginalis among Women Recruited in RESPECT-2, an HIV Prevention Trial D Helms 1, D Mosure 1, T Peterman 1, C Metcalf.

Gonorrhea Sexually Transmitted Disease Surveillance 2008 Division of STD Prevention.

Sexually Transmitted Disease Surveillance 2011 Division of STD Prevention.

Sexually Transmitted Disease Surveillance 2013 Division of STD Prevention.

Illustrating HIV/AIDS in the United States African American University Treatment and Science College Training Alexandra Ricca, MPH Emory University Friday,

Bernard M. Branson, M.D. Associate Director for Laboratory Diagnostics Divisions of HIV/AIDS Prevention National Center for HIV/AIDS, Viral Hepatitis,

Infertility Prevention Project Region I June 1, 2009 Wells Beach, Maine Infertility Prevention Project Region I June 1, 2009 Wells Beach, Maine Steven.

Application of an Epi Profile: Gonorrhea in the U.S. Region V Gonorrhea Control Meeting.

The findings and conclusions in this report are those of the authors and do not necessarily represent the official position of the Centers for Disease.

Gonorrhea in New York City Epidemiology, Disease Control Activities, and Challenges Presented by: Julia A. Schillinger, MD, MSc CAPT USPHS Bureau of STD.

Sexually Transmitted Disease Surveillance 2011 Division of STD Prevention.

SSuN Cycle 2 Conference call #5 Population-based gonorrhea surveillance Lori Newman & Kristen Mahle November 13, 2008.

Using HIV Surveillance to Achieve High Impact Prevention Irene Hall, PhD, FACE AIDS 2012 High-Impact Prevention: Reducing the HIV Epidemic in the United.

Alliance Discussion with Office of AIDS: November HIV/AIDS Surveillance Surveillance overview HIV Incidence Surveillance Second Surveillance Stakeholder.

STD Surveillance Network (SSuN) Cycle 2 Objectives Lori Newman & Kristen Mahle SSuN Principal Collaborators Meeting Atlanta, GA December 2, 2008.

SSuN Cycle 2 SSuN Part B Laboratory Component: Trichomonas Resistance Evaluation Bob Kirkcaldy, Lori Newman, Kristen Mahle December 4, 2008.

SSuN: MSM prevalence monitoring and HIV Testing in STD Clinics Kristen Mahle & Lori Newman SSuN Call #3 Oct 30, 2008.

All Slides Sexually Transmitted Disease Surveillance 2002 Division of STD Prevention.

MLAB Microbiology Keri Brophy-Martinez Public Health & The Microbiology Lab.

GONORRHEA Sexually Transmitted Disease Surveillance 2009 Division of STD Prevention.

STDs in Adolescents and Young Adults Sexually Transmitted Disease Surveillance 2007 Division of STD Prevention.

Bob Kirkcaldy, Nicholas Gaffga, Lori Newman

Public Health Response to Traumatic Brain Injury

Sexually Transmitted Disease Surveillance 2013 Division of STD Prevention.

STDs in Adolescents and Young Adults Sexually Transmitted Disease Surveillance 1999 Division of STD Prevention.

Sexually Transmitted Disease Surveillance 2013 Division of STD Prevention.

STD’s in Adolescents and Young Adults Sexually Transmitted Disease Surveillance 2001 Division of STD Prevention.

STDs in Men Who Have Sex with Men Sexually Transmitted Disease Surveillance 2009 Division of STD Prevention.

Other Sexually Transmitted Diseases Sexually Transmitted Disease Surveillance 2009 Division of STD Prevention.

National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division of Sexually Transmitted Disease Prevention.

National Center for HIV/AIDS, Viral Hepatitis, STD, and TB Prevention Division of Sexually Transmitted Disease Prevention.

STDs in Adolescents and Young Adults Sexually Transmitted Disease Surveillance 2004 Division of STD Prevention.

GONORRHEA Sexually Transmitted Disease Surveillance 2010 Division of STD Prevention.

STDs in Persons Entering Corrections Facilities Sexually Transmitted Disease Surveillance 2003 Division of STD Prevention.

STDs in Persons Entering Corrections Facilities Sexually Transmitted Disease Surveillance 2001 Division of STD Prevention.

Monitoring HIV risk behaviors among heterosexual couples: Challenges and lessons learned Amy Lansky, Tricia Martin, Melissa Cribbin Behavioral Surveillance.

Robert D. Kirkcaldy, MD, MPH

Lizzi Torrone, MSPH, PhD Lead, Surveillance & Special Studies Team

Evaluation Report: April 1, 2015 – March 31, 2016

Evaluation Period: January 1, 2016 – December

CSTE Applied Epidemiology Fellow

Gonococcal Isolate Surveillance Project (GISP)

Tim McAfee, M.D., M.P.H. Director, CDC Office on Smoking and Health

Amy Lansky, Elizabeth DiNenno Behavioral Surveillance Team

Suicide Prevention Debra Houry, MD, MPH Director

National STD Prevention Conference

Gonorrhea Sexually Transmitted Disease Surveillance 2010

National STD Prevention Conference

New CHEST Editorial Board Members

Infertility Prevention Project Coordinator CDC/CCID/NCHHSTP/DSTDP/PTB

Poster Title: Background and Introduction Methods and Results

Varicella Vaccine Efficacy Estimates

Washington State’s SSuN Project: Overview and Population Sampling Schema Principal Collaborators Meeting Atlanta, GA December 2009.

MSM Attending STD Clinics HIV Testing More Frequently: Implications for HIV Prevention and Surveillance D Helms1, H Weinstock1, K Mahle1, A Shahkolahi1,2,

Presentation transcript:

Trichomonas Vaginalis Antimicrobial Resistance Activity— SSuN, 2008–2010 Robert D. Kirkcaldy, MD, MPH Epidemic Intelligence Service (EIS) Officer Division of STD Prevention

Objectives Identify prevalence of Trichomonas vaginalis (TV) among STD clinic attendees Describe demographic & clinical characteristics of TV cases, esp. those exhibiting resistance Identify prevalence of in vitro antimicrobial resistance among TV isolates TV = Trichomonas vaginalis

Timing of TV Specimen Collection, 2009 AMJJulAugSO ND San Francisco Seattle Philadelphia Denver New York City Birmingham

Trichomonas Vaginalis Specimen Update* Outcome n (%) Specimens received at CDC 281 Specimens assayed 246 (88) Non-viable 30 (11) In culture 5 (2) * As of 30 November, 2009

Percentage of T. Vaginalis Specimens Assayed at CDC, by site Percentage SSuN Site 76% 93% 69% 90% 94% 88%

in vitro Metronidazole Resistance* among TV isolates SSuN Siten (%) NYC1 (2) Philadelphia4 (8) Birmingham0 (0) Denver3 (7) San Francisco2 (4) Seattle3 (6) Total13 (5) * MLC ≥ 50 μg/mL under aerobic conditions

Frequencies of Metronidazole MLC* results (n=243) MLC* (μg/mL) Number of specimens Median = 6.3 * MLC = Minimum Lethal Concentration under aerobic conditions In vitro resistance MinimalModHigh

Challenges Faced CDC laboratory capacity was less than projected –Needed to cap number of specimens Transient poor survivability at selected sites

Looking Ahead to 2010 Each site to collect additional 50 specimens CDC lab planning to increase capacity ‘Cap’ on specimen volume not planned –Except for very high volume site: ~ 10–15/week

Timing of TV Specimen Collection, 2010 AMayJunJulAugS San Francisco Seattle Philadelphia Denver New York City Birmingham MarFJ

CDC. Public Health Image Library Thank you!

Frequencies of MLC categories, NYC Minimum Lethal Concentration (μg/mL) Number of specimens Median=3.1

Frequencies of MLC categories, Philadelphia Minimum Lethal Concentration (μg/mL) Number of specimens Median=3.1

Frequencies of MLC categories, Birmingham Minimum Lethal Concentration (μg/mL) Number of specimens Median=12.5

Frequencies of MLC categories, Denver Minimum Lethal Concentration (μg/mL) Number of specimens Median=3.1

Frequencies of MLC categories, San Francisco Minimum Lethal Concentration (μg/mL) Number of specimens Median=3.1

Frequencies of MLC categories, Seattle Minimum Lethal Concentration (μg/mL) Number of specimens Median=6.3

Prevalence of in vitro Metronidazole Resistance* 8% 7% 6% 4% 2% * MLC ≥ 50 ug/dL 5% Percentage Include confidence intervals? SSuN Site

Prevalence of in vitro Metronidazole Resistance* (n=243) Colorado Washington California San Francisco Seattle Denver New York NYC Pennsylvania Philadelphia Alabama Birmingham 2% 8% 7% 4% 6% 0% * MLC ≥ 50 ug/dL Total = 5%

Acknowledgements CDC NYC Philadelphia Birmingham Denver San Francisco Seattle The findings and conclusions in this presentation are those of the authors and do not necessarily represent the official position of the Centers for Disease Control and Prevention